Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InterDigital, Inc.IDCC · Entity 3629 | CLO, GC & Corp Sec | October 15, 2021 | October 19, 2021 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | SVP, General Counsel & Sec. | February 28, 2018 | March 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InterDigital, Inc.
Report date October 15, 2021 · Filed October 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,519.9925 |
Ending reported balance
After 2021-10-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-10-15 · Grant · Acquired 6,216 · Balance 22,442.7043 F1: The transaction reported represents the partial vesting of an award of performance-based restricted stock units granted to the reporting person on March 31, 2020 pursuant to the company's 2017 Stock Incentive Plan in accordance with the 2020 Long-Term Compensation Program. Based on the achievement of two Milestone goals, 40% of the reporting person's target performance-based restricted stock unit award, or 6,216 restricted stock units, vested on October 15, 2021. Row 2 · 2021-10-15 · Tax withholding · Disposed 1,922 · Balance 20,520.7043 F2: The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability in connection with the transaction described in Note 1. Row 3 · 2021-10-15 · Disposition to issuer · Disposed 0.7118 · Balance 20,519.9925 F3: The transaction reported reflects the cash settlement of fractional shares in connection with the vesting of restricted stock units, as described in Note 1. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported represents the partial vesting of an award of performance-based restricted stock units granted to the reporting person on March 31, 2020 pursuant to the company's 2017 Stock Incentive Plan in accordance with the 2020 Long-Term Compensation Program. Based on the achievement of two Milestone goals, 40% of the reporting person's target performance-based restricted stock unit award, or 6,216 restricted stock units, vested on October 15, 2021.
F2: The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability in connection with the transaction described in Note 1.
F3: The transaction reported reflects the cash settlement of fractional shares in connection with the vesting of restricted stock units, as described in Note 1.
Vanda Pharmaceuticals Inc.
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,073 |
Ending reported balance
After 2018-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-28 · Grant · Acquired 30,000 · Balance 118,733 F1: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Row 2 · 2018-03-01 · Sale · Disposed 3,660 · Balance 115,073 F2: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2028-02-27 | Direct | 70,000 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Grant · Acquired 70,000 · Balance 70,000 F4: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
F2: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
F3: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2021 Filed Oct 19, 2021 16:31 UTC | InterDigital, Inc. IDCC · Entity 3629 | Disposition to issuerCommon Stock | 0.7118 | $68.44 | $48.72 |
DisclosureSEC source: 0001209191-21-060923 · doc4.xml · nonDerivative · entry 3 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,519.9925 F3 · kind: The transaction reported reflects the cash settlement of fractional shares in connection with the vesting of restricted stock units, as described in Note 1. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 16:31 UTC | InterDigital, Inc. IDCC · Entity 3629 | Tax withholdingCommon Stock | 1,922 | $68.44 | $131,541.68 |
DisclosureSEC source: 0001209191-21-060923 · doc4.xml · nonDerivative · entry 2 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,520.7043 F2 · kind: The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability in connection with the transaction described in Note 1. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 16:31 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 6,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060923 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,442.7043 F1 · kind: The transaction reported represents the partial vesting of an award of performance-based restricted stock units granted to the reporting person on March 31, 2020 pursuant to the company's 2017 Stock Incentive Plan in accordance with the 2020 Long-Term Compensation Program. Based on the achievement of two Milestone goals, 40% of the reporting person's target performance-based restricted stock unit award, or 6,216 restricted stock units, vested on October 15, 2021. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:44 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 74.7731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048814 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,226.7043 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:04 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 68.5221 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029257 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,151.9312 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 15:09 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 6,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024498 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,083.4091 F1 · kind: Restricted stock units granted pursuant to the company's 2017 Equity Incentive Plan in accordance with the company's long-term compensation program. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 15:25 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 38.2776 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006046 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,463.4091 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 16:10 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 45.3709 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056326 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,425.1315 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 17:28 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 42.7515 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043632 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,379.7606 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:26 UTC | InterDigital, Inc. IDCC · Entity 3629 | Disposition to issuerCommon Stock | 929 | $55.38 | $51,448.02 |
DisclosureSEC source: 0001209191-20-037480 · doc4.xml · nonDerivative · entry 2 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337.0091 F2 · kind: The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability in connection with the transaction described in Note 1. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:26 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 3,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037480 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,266.0091 F1 · kind: The transaction reported represents the partial vesting of an award of performance-based restricted stock units granted to the reporting person on March 31, 2020 pursuant to the company's 2017 Stock Incentive Plan in accordance with the 2020 Long-Term Compensation Program. Based on the achievement of a Milestone goal, 20% of the reporting person's target performance-based restricted stock unit award, or 3,030 restricted stock units, vested on June 15, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:43 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 16.2692 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025665 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,236.0091 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:40 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 5,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022587 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,219.7399 F1 · kind: Restricted stock units granted pursuant to the company's 2017 Equity Incentive Plan in accordance with the company's long-term compensation program. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 17:01 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 5.7399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004882 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,177.7399 F1 · kind: Restricted stock units received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to the reporting person. Dividend equivalents accrue with respect to unvested restricted stock units when and as cash dividends are paid on InterDigital, Inc.'s common stock. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 16:42 UTC | InterDigital, Inc. IDCC · Entity 3629 | GrantCommon Stock | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003701 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · CLO, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,172 F1 · kind: Restricted stock units granted pursuant to the company's 2017 Equity Incentive Plan in accordance with the company's long-term compensation program. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 17:33 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,660 | $18.71 | $68,473.11 |
DisclosureSEC source: 0001209191-18-015878 · doc4.xml · nonDerivative · entry 2 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,073 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:33 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001209191-18-015878 · doc4.xml · derivative · entry 3 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-02-27 F4 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:33 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-015878 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,733 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002054 · doc4.xml · derivative · entry 5 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F8 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002054 · doc4.xml · derivative · entry 4 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F8 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 10,367 | $15.20 | $157,564.92 |
DisclosureSEC source: 0001209191-18-002054 · doc4.xml · nonDerivative · entry 3 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,733 F5 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-002054 · doc4.xml · nonDerivative · entry 2 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Each RSU was previously reported on Table II on a Form 4 filed with the SEC on February 17, 2016. F2 · price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F3 · balance_after: Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-002054 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Restricted Stock Unit ("RSU") was previously reported on Table II on a Form 4 filed with the Securities and Exchange Commission ("SEC") on September 15, 2015. F2 · price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F3 · balance_after: Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001209191-17-017789 · doc4.xml · derivative · entry 2 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-02-28 F3 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments beginning March 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each monthly vesting date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantRestricted Stock Unit | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-017789 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 F1 · shares: The Restricted Stock Units ("RSU") shall vest in four (4) equal annual installments beginning March 1, 2018, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F2 · price: Each RSU represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:07 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002214 · doc4.xml · derivative · entry 5 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:07 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002214 · doc4.xml · derivative · entry 4 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:07 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 10,900 | $15.51 | $169,089.52 |
DisclosureSEC source: 0001209191-17-002214 · doc4.xml · nonDerivative · entry 3 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.33 to $15.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:07 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002214 · doc4.xml · nonDerivative · entry 2 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:07 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002214 · doc4.xml · nonDerivative · entry 1 Gulino Richard L. · CIK 0001652208 · SVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.